Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC11A2 | P49281 | 5/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | CD4 | P01730 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2358175 | 0.84 | CD4 (0.42) | CD4HSD11B1 | |
| SCHEMBL2355036 | 0.84 | MEN1 (0.49) | CD4HSD11B1MEN1KMT2AALDH1A1 | |
| SCHEMBL2355545 | 0.81 | ALDH1A1 (0.52) | GRM5CD4KDM4EHSD11B1ALDH1A1 | |
| SCHEMBL2347843 | 0.78 | LMNA (0.46) | CD4LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL2241520 | 0.75 | MEN1 (0.49) | CD4HSD11B1MEN1KMT2AALDH1A1 | |
| SCHEMBL2358797 | 0.75 | CD4 (0.56) | CD4LMNAALDH1A1POLB | |
| SCHEMBL2355923 | 0.75 | ALDH1A1 (0.61) | CD4KDM4EALDH1A1 | |
| SCHEMBL2346588 | 0.75 | CD4 (0.51) | CD4LMNAHSD11B1ALDH1A1TSHR | |
| SCHEMBL2357805 | 0.74 | LMNA (0.48) | CD4LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL2358075 | 0.73 | CD4 (0.41) | CD4MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748456-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-06-10 | — | — | US | claimed |
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | claimed |
| US-8748456-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-06-10 | — | — | US | disclosed |
| US-8748456-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-06-10 | — | — | US | disclosed |
| US-8748456-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-06-10 | — | — | US | disclosed |
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | disclosed |
| WO-2011101805-A1 | PYRAZOLO PIPERIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | NOX1, NOX4, NOX5 | SLC11A2 2548/4885GRM5 1226/4885CD4 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.